Arrotex Pharmaceuticals

What Arrotex Pharmaceuticals does

Arrotex Pharmaceuticals is Australia's largest and most diversified pharmaceutical provider, operating as a subsidiary of Australian-owned conglomerate DBG Health. The company supplies more than 350 prescription medicines across 1,298 SKUs to community pharmacies, public and private hospitals, and licensing partners across Australia and New Zealand, fulfilling approximately 1 in every 2 PBS (Pharmaceutical Benefits Scheme) scripts and representing an estimated 50% of Australia's total pharmaceutical volume. Its core product lines span generic medicines, branded prescription medicines, hospital medicines, biologics and biosimilars (including first-to-market launches with Celltrion), and innovative medicines licensed from multinational pharmaceutical partners such as CStone Pharmaceuticals, LENZ Therapeutics, George Medicines, Formosa Pharmaceuticals, Dong-A ST, Antengene, and Juniper Biologics.

Arrotex monetizes through a hybrid model: one-time and volume-based distribution of generics and biosimilars under the PBS framework, licensing royalties and milestone payments from multinational partners whose branded and innovative medicines it commercializes, and upfront plus gross-margin-share economics on exclusive licensing deals (24+ partnerships disclosed). Customer segments include patients (across cardiometabolic, oncology, ophthalmology, and musculoskeletal therapeutic areas), community pharmacies, public and private hospitals, and multinational pharmaceutical companies seeking an Australian commercialization partner. Adjacent operations include Arrovet (animal health) and VidaCorp (consumer health and beauty, housing PONi Cosmetics, esmi Skin Minerals, Lip Heroes, and Sun Skills), the latter created through the 2024 acquisition of Makeup Cartel from Point King Capital.

The company's go-to-market relies on its unmatched pharmacist and prescriber access, regulatory expertise across Australia's TGA and New Zealand's Medsafe, and an 8-office international footprint spanning Melbourne, Sydney, Auckland, New York, London, Amsterdam, and Singapore. Arrotex is ranked #1 in Australia for new product launches and operates the SupportEd patient support program with more than 320,000 enrolled patients. The business is privately held with no public listing, no disclosed funding rounds, and ownership consolidated under DBG Health.

Name

Arrotex Pharmaceuticals

Legal name

DBG Health

Website

https://arrotex.com.au

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Arrotex Pharmaceuticals is Australia's largest pharmaceutical provider, supplying 350+ prescription medicines and 1,298 SKUs to pharmacies and hospitals, fulfilling 1 in 2 PBS scripts, and licensing innovative medicines from 24+ multinational partners across Australia and New Zealand.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Generic pharmaceuticals
• Hospital medicines supply
• Biosimilars distribution
• Pharmaceutical licensing partnerships
• Prescription drug wholesale

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Generic Medicines: Arrotex provides branded and generic prescription medicines across the spectrum of therapeutic areas, fulfilling 1 in every 2 PBS (Pharmaceutical Benefits Scheme) scripts in Australia. This forms the core revenue base.
2. Branded Medicines: Arrotex serves as the Australian partner of choice for multinational pharmaceutical companies, representing and commercializing branded medicines. Over 15 years of proven success in representing branded medicines.
3. Innovative Medicines Licensing: Arrotex grants exclusive licenses to international pharma partners to commercialize their innovative medicines in Australia and New Zealand, receiving upfront payments, milestone payments, and royalties on sales.
4. Hospital Medicines: Arrotex is Australia's leading provider of hospital medicines, supplying a broad portfolio to public and private hospitals with robust supply infrastructure.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Arrotex Pharmaceuticals manufactures, supplies, and commercializes generic, branded, hospital, biologic, and biosimilar prescription medicines across Australia and New Zealand through a portfolio of more than 350 prescription medicines and 1,298+ SKUs. The company serves as the Australian commercialization partner of choice for multinational pharmaceutical companies via exclusive licensing deals (sugemalimab, VIZZ, GMRx2, APP13007, and others), and fulfils 1 in every 2 PBS scripts nationally. It also operates adjacent consumer health (VidaCorp) and animal health (Arrovet) businesses.

Product overview

Arrotex Pharmaceuticals is Australia's largest and most diversified pharmaceutical provider offering a platform of prescription medicines across multiple segments: (1) Generic Medicines - the core offering fulfilling 1 in 2 PBS scripts with 1,298 prescription SKUs; (2) Branded Medicines - representing multinational pharmaceutical brands; (3) Innovative Medicines - licensing partnerships for novel therapies; (4) Hospital Medicines - leading provider to public and private hospitals; and (5) Biologics and Biosimilars - including first-to-market biosimilars with Celltrion. The company also operates consumer health through VidaCorp (acquired beauty brands PONi Cosmetics, esmi Skin Minerals, Lip Heroes, Sun Skills) and animal health through ArroVet. Licensed products include sugemalimab (CStone), VIZZ (LENZ), GMRx2 (George Medicines), and APP13007 (Formosa Pharmaceuticals). The company maintains 24+ multinational partnerships and operates across Australia, New Zealand, and international offices.

Differentiator

Problem solved

Functional benefit

Brands

• VidaCorp: Consumer health and beauty enterprise created from the Makeup Cartel acquisition
• Arrovet
• PONi Cosmetics
• esmi Skin Minerals
• Lip Heroes
• Sun Skills

Products and services

• Generic Medicines Arrotex offers the most extensive range of prescription generic medicines across therapeutic areas, fulfilling 1 in every 2 PBS scripts in Australia with 1,298+ prescription SKUs, supplied to community pharmacies and hospitals.
• Branded Medicines Arrotex represents and commercializes branded medicines for multinational pharmaceutical companies in Australia, acting as the strategic partner of choice to grow and protect their brands in the Australian market.
• Innovative Medicines (Licensing Partnerships) Exclusive licensing and commercialization partnerships providing Australian patients access to innovative medicines from international pharma companies, leveraging Arrotex's TGA/Medsafe regulatory expertise and distribution platform.
• Hospital Medicines Broad portfolio and range of presentations of hospital medicines supplied to public and private hospitals across Australia, supported by robust supply infrastructure and innovative solutions.
• Biologics and Biosimilars Largest biologics and biosimilars range in Australia, including first-to-market biosimilars launched in partnership with Celltrion, supplied to pharmacies and hospitals.
• SupportEd Patient Support Program Integrated patient support program providing therapy support to patients enrolled across Arrotex's prescription medicines portfolio, with more than 320,000 patients enrolled.
• OraDerm Dermatology brand represented and commercialized by Arrotex in Australia.
• Sugemalimab (Australia and New Zealand) Anti-PD-L1 antibody from CStone Pharmaceuticals, licensed to Arrotex for exclusive commercialization across approved and future indications in Australia and New Zealand.
• VIZZ (Aceclidine Ophthalmic Solution) FDA-approved aceclidine ophthalmic solution for presbyopia treatment from LENZ Therapeutics, licensed to Arrotex for exclusive commercialization in Australia and New Zealand.
• GMRx2 (Triple-combination Hypertension Treatment) Single-pill triple-combination hypertension treatment from George Medicines, licensed to Arrotex for exclusive commercialization in Australia and New Zealand, addressing hypertension affecting approximately 1 in 3 adults in both countries.
• APP13007 (Clobetasol Propionate Ophthalmic Suspension) FDA-approved clobetasol propionate ophthalmic suspension from Formosa Pharmaceuticals for treatment of inflammation and pain following ocular surgery, licensed to Arrotex for exclusive commercialization in Australia and New Zealand, representing approximately 250,000 cataract surgeries annually in the territory.
• Arrovet (Animal Health) Animal health business under DBG Health, providing veterinary pharmaceutical products and services.

Quantifiable outcome

• 1 in every 2 PBS scripts in Australia fulfilled by Arrotex
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core.

• CStone PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 25 June 2026CStone Pharmaceuticals entered an exclusive commercialization agreement with Arrotex for sugemalimab in Australia and New Zealand. CStone will receive an upfront payment plus regulatory and commercial milestone payments, while supplying the drug and sharing profits. This is sugemalimab's fifth international partnership, extending its global footprint to over 60 countries across Europe, Middle East and Africa, Latin America, and Oceania.
• LENZ TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 24 June 2026LENZ Therapeutics granted Arrotex exclusive licensing and commercialization rights for VIZZ (aceclidine ophthalmic solution), an FDA-approved presbyopia eye drop therapy, in Australia and New Zealand. LENZ receives an upfront payment plus a share of gross margin from product sales. This is LENZ's fifth ex-US commercialization partnership for VIZZ, which received FDA approval in July 2025 and has been commercially available in the United States since October 2025.
• George MedicinescoreOEM/ Whitelabel/ Licensing Partner · 16 March 2026George Medicines entered an exclusive licensing and supply agreement granting Arrotex exclusive rights to commercialize GMRx2, its single-pill triple-combination hypertension treatment, in Australia and New Zealand. George Medicines will receive an upfront licensing fee, commercial milestone payments, and tiered royalties on future sales. Arrotex will seek regulatory approval from Australia's TGA and New Zealand's Medsafe.
• Formosa PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 23 February 2026Taiwan-based Formosa Pharmaceuticals entered an exclusive licensing agreement with Arrotex for commercialization of its FDA-approved clobetasol propionate ophthalmic suspension (APP13007) in Australia and New Zealand, covering treatment of inflammation and pain following ocular surgery. The deal includes upfront payments, regulatory milestones, sales milestones, and royalty considerations, with the territory representing approximately 250,000 cataract surgeries annually.
• Dong-A STcoreOEM/ Whitelabel/ Licensing PartnerArrotex signed an exclusive licensing agreement with Korea-based Dong-A ST for innovative medicines. This partnership is highlighted as a news item on the Arrotex website under the 'Innovative Medicines' section.
• AntengenecoreOEM/ Whitelabel/ Licensing PartnerArrotex partnered with Antengene on a therapy for multiple myeloma. This partnership was highlighted in the news section of the Arrotex website.
• CelltrioncoreOEM/ Whitelabel/ Licensing PartnerArrotex and Celltrion launched two first-to-market biosimilars. This partnership was highlighted in the news section as a key biosimilar initiative.
• Juniper BiologicscoreOEM/ Whitelabel/ Licensing PartnerArrotex entered an exclusive partnership with Juniper Biologics, highlighted as a strategic growth initiative in the news section.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sigma Healthcare: Australia's largest full-line pharmaceutical distributor, wholesaling PBS-listed medicines to community pharmacies and hospitals — directly comparable to Arrotex on product breadth, customer base, and PBS volume exposure.
• Australian Pharmaceutical Industries (Wesfarmers Health): Leading Australian pharmaceutical distributor and pharmacy services operator (acquired by Wesfarmers in 2021), serving community pharmacies with branded, generic, and OTC medicines — overlapping customer base and distribution model with Arrotex.
• EBOS Group: Trans-Tasman healthcare distributor operating across Australia and New Zealand, supplying prescription medicines, consumer health, and animal health products — comparable to Arrotex's AU/NZ dual-market presence and product breadth.
• Clifford Hallam Healthcare (CHH): Australian pharmaceutical and consumer health wholesaler distributing to community pharmacies and hospitals — directly comparable to Arrotex's branded/generic wholesale model.
• Mayne Pharma: Australian specialty and generic pharmaceutical company offering branded generics, women's health, and dermatology products — comparable to Arrotex's branded generics portfolio and specialty care focus.

Broad incumbents

• CSL Limited: Australia's largest biopharmaceutical company focused on plasma-derived therapies and vaccines — overlapping Australian pharma footprint but specialized in plasma/biologics rather than Arrotex's distribution-led model.
• Aspen Pharmacare: Global specialty and generic pharmaceutical manufacturer/distributor with operations across emerging and developed markets — comparable branded-generic-distribution model but with broader geographic and therapeutic scope than Arrotex.
• Apotex: Canadian generic pharmaceutical manufacturer with global operations producing prescription generics and biosimilars — comparable to Arrotex's generic manufacturing and supply footprint though heavier on manufacturing than distribution.
• Sandoz Group: Global leader in generics and biosimilars (spun out of Novartis) — provides large-scale pharmaceutical supply and biosimilars competitive overlap with Arrotex's Celltrion-partnered biosimilar franchise.
• Mundipharma: Multinational pharmaceutical company with established Asia-Pacific presence marketing branded specialty medicines — comparable business model of representing licensed/marketed brands in regional markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/arrotex-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arrotex Pharmaceuticals